Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

| Pacira Pharr Form 4 June 07, 201 | naceuticals, Inc. | | | | | | | | | | | |
|--|---|--|--|--|---------|-----------|-------|---|---|-------------------------------------|--|--|
| | | | | | | | | | OMB A | OMB APPROVAL | | |
| - | UNITED | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 | | | | | | | | 3235-0287 | | |
| Check th if no long subject to Section 1 Form 4 o | der. | | - | | | ~~ | | | Expires: | January 31, 2005 | | |
| | o STATEN 16. or | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP O SECURITIES | | | | | | | Estimated average burden hours per response 0.5 | | | |
| Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 | | | | | | | | | | | | |
| (Print or Type Responses) | | | | | | | | | | | | |
| 1. Name and Address of Reporting Person <u>*</u> MIDDLETON FRED A | | | 2. Issuer Name and Ticker or Trading Symbol Pacira Pharmaceuticals, Inc. [PCRX] | | | | | 5. Relationship of Reporting Person(s) to Issuer | | | | |
| (Last) | (First) (I | Middle) | 3. Date of Earliest Transaction | | | | - | (Chec | k all applicabl | e) | | |
| | | | | (Month/Day/Year) 06/05/2013 | | | | X Director Officer (give below) | % Owner ler (specify | | | |
| (Street) 4. If Amendr | | | | | - | | | 6. Individual or Joint/Group Filing(Check | | | | |
| Filed(Mo | | | | nth/Day/Year) | | | | Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting | | | | |
| SAN WATEO, CA 94402 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | |
| | | - | | | | | - | · · - | 6. | Ily Owned 7. Nature of | | |
| 1.Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | Executio any | | 3.4. Securities AcquiredTransactior(A) or Disposed of (D)Code(Instr. 3, 4 and 5)(Instr. 8) | | | | 5. Amount of Securities Beneficially Owned | Ownership | Indirect Beneficial Ownership | | |
| | | | | | | (A) or | | Following Reported Transaction(s) | Indirect (I) (Instr. 4) | (Instr. 4) | | |
| | | | | Code V | Amount | (D) | Price | (Instr. 3 and 4) | | G | | |
| Common Stock | 06/05/2013 | | | J | 316,660 | D | \$0 | 45,102 | I | See Footnotes (1) (4) (5) | | |
| Common Stock | 06/05/2013 | | | J | 241,185 | D | \$0 | 174,898 | I | See Footnotes (2) (4) (5) | | |
| Common Stock | 06/05/2013 | | | J | 7,433 | А | \$0 | 70,399 | D (3) (4) (5) | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 4. Transactic Code (Instr. 8) | 5. ofNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | ; | ate | 7. Titl Amou Under Securi (Instr. | int of rlying | 8. Price of Derivative Security (Instr. 5) | 9. Nu Deriv Secur Bene Owno Follo Repo Trans (Instr |
|---|---|---|--|---|---------------------|--------------------|---|--|---|---|
| | | | Code V | (A) (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | |

Reporting Owners

M C/ 40 SA

S

/s M

| Reporting Owner Name / Address | | Relationships | | | | | | |
|--|-----------------------------------|---------------|-----------|---------|-------|--|--|--|
| in porting o | | | 10% Owner | Officer | Other | | | |
| IIDDLETON FREI /O SANDERLING 00 SOUTH EL CAI AN MATEO, CA 9 | VENTURES MINO REAL, SUITE 1200 | Х | | | | | | |
| ignatures | | | | | | | | |
| s/ Fred A. Iiddleton | 06/07/2013 | | | | | | | |
| <u>**</u> Signature of Reporting Person | Date | | | | | | | |

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The securities are held directly by Sanderling Venture Partners VI Co-Investment Fund, L.P. On June 5, 2013, Sanderling Venture Partners VI Co-Investment Fund, L.P. distributed an aggregate of 316,660 shares of the Issuer's common stock pro rata to its partners for

 (1) Faithers VI Co-Investment Fund, E.F. distributed an aggregate of 510,000 shares of the issuer's common stock pro-fait to its partners for no consideration (the "First Distribution"). The address for Sanderling Venture Partners VI Co-Investment Fund, L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402.

The securities are held directly by Sanderling Venture Partners VI, L.P. On June 5, 2013, Sanderling Venture Partners VI, L.P. distributed an aggregate of 241,185 shares of the Issuer's common stock pro rata to its partners for no consideration (the "Second Distribution"). The

(2) an aggregate of 241,165 states of the issuer's common stock pro fata to its particles for no consideration (the "second Distribution"). The address for Sanderling Venture Partners VI, L.P. is c/o Sanderling Ventures, 400 South El Camino Real, Suite 1200, San Mateo, CA 94402

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

(3) The securities are held directly by My Middleton. Mr. Middleton received 4,036 shares of the Issuer's common stock as a result of the First Distribution and 3,397 shares of the Issuer's common stock as a result of the Second Distribution.

Fred Middleton, a member of the Board of Directors of the Issuer, is a managing director of Middleton, McNeil, Mills & Associates VI, LLC, which has the ultimate voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. and

- (4) he may be deemed to have voting and investment power over shares held of record by Sanderling Venture Partners VI, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership and Sanderling Venture Partners VI Co-Investment Fund, L.P. Mr. Middleton is the owner of Sanderling Ventures Management VI and he may be deemed to have voting and investment power over shares held of record by Sanderling Ventures Management VI.
- (5) Mr. Middleton disclaims beneficial ownership over the shares held by Sanderling Ventures and its affiliates, except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.